PLAU and cancer: MiR-193b was demonstrated to negatively regulate tumor migration, invasion and metastasis through targeting urokinase type plasminogen activator (PLAU), dimethylaminohydrolase 1 (DDAH1), cyclin D1 (CCND1) and ETS1 in several cancer cell lines [26–30].